Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Journal of Clinical Oncology.
Times cited: 121
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
New England Journal of Medicine.
Times cited: 1529